lifestyle.capitolhilltimes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
GENPREX, INC.
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
March 18, 2026
Genprex to Participate at BIO Europe Spring 2026
March 10, 2026
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
February 23, 2026
Genprex Announces IP Australia’s Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
February 16, 2026
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
January 12, 2026
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
January 9, 2026
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
January 9, 2026
Data from Genprex’s Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
December 1, 2025
Genprex Announces European Patent Office’s Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
November 4, 2025
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 28, 2025
1
2
Next Page
→